The biotechnology sector has been instrumental in bringing Covid-19 under control. It was not the traditional large pharmaceutical vaccine specialists that led the way, but the innovative biotech firms such as BioNTech and Moderna. These companies have turned a much-discussed idea – vaccines based on RNA, a new approach – into a product and have manufactured millions of doses. That has led to valuations of some of the innovative small-cap companies accelerating to eye-wateringly high levels.
It is easy to get caught up in the hype of investing in stocks with rapidly rising share prices. However, we rely on fundamental analysis in making our investment decisions and look out for companies that boast a compelling roster of innovative products. We also ensure that these companies have experienced managers to help the business deliver long-term growth. We also seek out stocks that are fairly valued and we do not chase overhyped small-cap biotechs. In our opinion, these three stocks have good pipelines, strong management teams and fair valuations.
Orphan diseases: a high-growth niche
The experienced management team at Horizon Therapeutics (Nasdaq: HZNP) has turned the company into a high-growth “orphan disease” specialist. Orphan diseases affect a small number of patients, but still command good pricing power and favourable patent protections.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
One of the company’s current drugs is Tepezza, used to treat a rare condition called thyroid eye disease. The launch of this drug has been very successful, with peak sales estimated to exceed $3bn. In February 2021, in order to maintain its pipeline of new drugs, the company bought another orphan-disease company called Viela Bio.
Tackling multiple maladies
Alnylam Pharmaceuticals (Nasdaq: ALNY) has developed an RNA-platform technology that can regulate the production of various protein cells to help treat a number of different diseases. There are currently four drugs approved, which help to treat diseases caused by genetic mutations, in addition to a broad, growing, and therapeutically diversified pipeline of projects with the potential for high sales.
The company is adapting this technology to treat a range of other diseases. Some of these conditions are also caused by genetic abnormalities, while more common ailments such as hepatitis B and hypertension will also be tackled.
Shifting from HIV to cancer
Gilead Sciences (Nasdaq: GILD) is a mature biotech that built its business on HIV treatments. In 2011 it acquired Pharmasset, which had a pipeline drug to treat and cure hepatitis-C infections. The hepatitis-C franchise became hugely successful, generating peak sales of $10bn. But its growth rate dwindled soon after, as patients left treatment once they were cured.
Since then, a new management team has refocused the company on oncology by acquiring Immunomedics for $21bn. The jury is still out as to whether this acquisition will be considered a success; it depends on the data from a large breast-cancer study expected to be made public later in 2021. Gilead Sciences has not taken part in the recent market rally as it is considered defensive, so it is trading on a relatively low-price earnings (p/e) multiple.
-
MoneyWeek experts' best investments for the next 25 yearsMoneyWeek's experts predict the best investments for the next quarter-century. Tips range from defence and agriculture to Vietnam and Jardine Matheson
-
How to navigate the ups and downs of investment marketsMax King has spent over 40 years managing a fund and investing privately. Here are the key lessons he has learnt
-
MoneyWeek experts pick the best investments for the next 25 years
MoneyWeek's experts predict the best investments for the next quarter-century. Tips range from defence and agriculture to Vietnam and Jardine Matheson
-
How to navigate the ups and downs of investment markets
Max King has spent over 40 years managing a fund and investing privately. Here are the key lessons he has learnt
-
MoneyWeek's best calls of the last 25 years – the key trends we got rightFrom the early days of the gold bull market and the credit crunch to the advent of populism and post-Covid inflation, MoneyWeek has made some excellent calls
-
'How I brought MoneyWeek to the masses'Launching MoneyWeek gave ordinary investors information – and hence power, says Merryn Somerset Webb
-
'Why I launched MoneyWeek'Inspired by The Week and uninspired by the financial press, Jolyon Connell decided it was time for a new venture. That's where MoneyWeek came in
-
'My predictions for the next 25 years'Opinion What will the world look like when MoneyWeek celebrates its 50th birthday? Matthew Lynn shares his predictions
-
How have central banks evolved in the last century – and are they still fit for purpose?The rise to power and dominance of the central banks has been a key theme in MoneyWeek in its 25 years. Has their rule been benign?
-
What MoneyWeek has learnt in the last 25 yearsFinancial markets have suffered two huge bear markets and a pandemic since MoneyWeek launched. Alex Rankine reviews key trends and lessons from a turbulent time
